- Current report filing (8-K)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 12, 2012

MEDTOX SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)


Delaware	1-11394	95-3863205
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


402 West County Road D, St. Paul, Minnesota		55112
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

x	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On July 12, 2012, MEDTOX Scientific, Inc. announced results for the second quarter ended June 30, 2012, as described in the press release attached as Exhibit 99.1.

- 2 -

Item 8.01. Other Events

On July 12, 2012, MEDTOX Scientific, Inc. issued a press release announcing the Company’s results for the quarter ended June 30, 2012. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herewith by reference.

- 3 -

Item 9.01. Financial Statements and Exhibits .

(c)	Exhibits .

The following exhibit is filed as part of this report:


Exhibit No.		Description
99.1		MEDTOX Scientific, Inc. Press Release, dated July 12, 2012.

- 4 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTOX Scientific, Inc.

Date: July 12, 2012 By: /s/ Richard J. Braun

Name: Richard J. Braun

Title: Chief Executive Officer

- 5 -

INDEX TO EXHIBITS